• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

IRX Therapeutics to Present Phase 2b Results at 3rd European Conference on Head & Neck Oncology

Posted on: Friday, 2 May 2008, 12:01 CDT

IRX Therapeutics, a privately-held company dedicated to the discovery and development of proprietary drugs for the treatment of cancer and viral diseases, today announced that findings from its Phase 2b clinical trial of IRX-2 will be presented at a symposium on May 8, 2008 at 15:45 during the 3rd European Conference on Head and Neck Oncology at the Westin Hotel in Zagreb, Croatia.

The symposium entitled, "IRX-2: Advancing the Role of Immunotherapy in Head and Neck Cancer" will include three presentations:

Theresa L. Whiteside, Ph.D. will present "Immunosuppressive Mechanisms in Head and Neck Cancer." Dr. Whiteside is Professor of Pathology, Immunology and Otolaryngology and is Director of the Immunologic Monitoring and Cellular Products Laboratory at the University of Pittsburgh School of Medicine.

Gregory T. Wolf, M.D., F.A.C.S., the Principal Investigator for the Phase 2b trial of IRX-2, will present "Clinical Experience of IRX-2 in Head and Neck Cancer and Future Directions." Dr. Wolf is the Professor and Chair, Department of Otolaryngology and Head and Neck Surgery at the University of Michigan as well as Director of the University of Michigan Head and Neck Oncology SPORE Program.

John W. Hadden, M.D., Founder and Chief Scientific Officer, IRX Therapeutics will conclude the symposium by presenting "IRX-2, a Novel Immunotherapeutic Approach to Head and Neck Cancer."

IRX Therapeutics will also be sponsoring an exhibit booth at the Conference highlighting the upcoming global Phase 3 clinical trial of IRX-2 and the opportunity for clinicians to participate in the clinical trial.

About Head and Neck Cancer

Head and neck cancer is a deadly disease that often goes undiagnosed until it is at an advanced stage. There are 500,000 new cases worldwide each year, with about 50,000 new cases in the United States. Head and neck cancer is associated with high rates of recurrence and mortality and is understood to be highly immunosuppressive. The current standard of care for newly diagnosed head and neck cancer is primarily curative surgery followed by radiation therapy or, in some cases, chemoradiation. There is no approved neoadjuvant therapy for these patients. The immunosuppressive nature of head and neck cancer creates a potential role for immunotherapy as a neoadjuvant intervention in the treatment of this disease.

About IRX Therapeutics

IRX Therapeutics is a privately-held immunotherapy company founded by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology. The Company's product platform seeks to restore an effective cellular immune response for the treatment of advanced cancers and viral diseases by correcting both dendritic cell and T-cell defects. An effective immune response is essential for the eradication of viruses and tumors.

The Company's lead product, IRX-2 (citoplurikin), received Fast Track designation by the Food and Drug Administration. Phase 2a and 2b clinical trials in late-stage head and neck cancer patients have been completed.

For more information on IRX Therapeutics, please visit the Company's website at http://www.irxtherapeutics.com.

Source: Business Wire

More News in this Category